Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease

Published experience with carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM) and extramedullary disease (EMD) is still limited. The current study aimed to assess the efficacy and safety of carfilzomib containing therapy regimens in EMD. We retrospectively analyzed 45 patients w...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancers (Basel)
Autors principals: Zhou, Xiang, Flüchter, Patricia, Nickel, Katharina, Meckel, Katharina, Messerschmidt, Janin, Böckle, David, Knorz, Sebastian, Steinhardt, Maximilian Johannes, Krummenast, Franziska, Danhof, Sophia, Einsele, Hermann, Kortüm, K. Martin, Rasche, Leo
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7225914/
https://ncbi.nlm.nih.gov/pubmed/32340174
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12041035
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars